UA84930C2 - Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения - Google Patents

Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения

Info

Publication number
UA84930C2
UA84930C2 UAA200613208A UAA200613208A UA84930C2 UA 84930 C2 UA84930 C2 UA 84930C2 UA A200613208 A UAA200613208 A UA A200613208A UA A200613208 A UAA200613208 A UA A200613208A UA 84930 C2 UA84930 C2 UA 84930C2
Authority
UA
Ukraine
Prior art keywords
inhibitors
intermediates
synthesis
protein kinase
pyrrole compounds
Prior art date
Application number
UAA200613208A
Other languages
English (en)
Ukrainian (uk)
Inventor
Габриэль Мартинез-Ботелла
Майкл Р. Хейл
Франсуа Мальтес
Квинг Танг
Юдит Штрауб
Original Assignee
Вертекс Фармасьютикалс Инкорпорейтед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вертекс Фармасьютикалс Инкорпорейтед filed Critical Вертекс Фармасьютикалс Инкорпорейтед
Publication of UA84930C2 publication Critical patent/UA84930C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Это изобретение касается соединений, которые используются как ингибиторы протеинкиназ.Изобретение предлагает также фармацевтически приемлемые композиции, которые содержат указанные соединения, и способы применения таких композиций в лечении разных болезней, состояний или расстройств.
UAA200613208A 2004-05-14 2005-05-13 Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения UA84930C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57130904P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
UA84930C2 true UA84930C2 (ru) 2008-12-10

Family

ID=35106760

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200613208A UA84930C2 (ru) 2004-05-14 2005-05-13 Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения

Country Status (26)

Country Link
US (6) US7354939B2 (ru)
EP (5) EP3943489A1 (ru)
JP (1) JP5132305B2 (ru)
CN (1) CN1976919A (ru)
AR (2) AR051735A1 (ru)
AU (1) AU2005245885B2 (ru)
BR (1) BRPI0511111A (ru)
CA (1) CA2566461C (ru)
CY (1) CY1122336T1 (ru)
DK (1) DK3305776T3 (ru)
ES (4) ES2513965T3 (ru)
HK (2) HK1203505A1 (ru)
HU (1) HUE047130T2 (ru)
IL (1) IL179207A0 (ru)
LT (1) LT3305776T (ru)
MX (1) MXPA06013209A (ru)
NO (1) NO20065727L (ru)
NZ (1) NZ551582A (ru)
PL (1) PL3305776T3 (ru)
PT (1) PT3305776T (ru)
RU (1) RU2376299C2 (ru)
SI (1) SI3305776T1 (ru)
TW (1) TW200607803A (ru)
UA (1) UA84930C2 (ru)
WO (1) WO2005113541A1 (ru)
ZA (1) ZA200609975B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10634677B2 (en) 2013-10-14 2020-04-28 Indiana University Research And Technology Corporation Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4808154B2 (ja) * 2003-03-13 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用な組成物
WO2005100342A1 (en) * 2004-03-26 2005-10-27 Vertex Pharmaceuticals, Incorporated Pyridine inhibitors of erk2 and uses thereof
WO2005113541A1 (en) * 2004-05-14 2005-12-01 Vertex Pharmaceuticals, Incorporated Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Ｅｒｋインヒビターとしてのピロリジン誘導体
CN101815711A (zh) * 2007-06-05 2010-08-25 先灵公司 多环吲唑衍生物及其作为erk抑制剂治疗癌症的用途
CA2714479A1 (en) 2008-02-21 2009-08-27 Schering Corporation Compounds that are erk inhibitors
CN102146074B (zh) * 2011-01-26 2013-02-06 江苏先声药物研究有限公司 吡咯衍生物的制备方法及应用
WO2012172093A1 (en) 2011-06-17 2012-12-20 Merz Pharma Gmbh & Co. Kgaa Dihydroindolizine derivate as metabotropic glutamate receptor modulators
US20160264536A1 (en) 2013-10-23 2016-09-15 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015095833A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
JP6678584B2 (ja) * 2013-12-20 2020-04-22 バイオメッド バレー ディスカバリーズ，インコーポレイティド Ｃｄｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがん処置
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
CA2934669C (en) * 2013-12-20 2022-10-04 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
AU2014368925A1 (en) * 2013-12-20 2016-07-21 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of MEK type I and ERK inhibitors
ES2918375T3 (es) * 2013-12-20 2022-07-15 Biomed Valley Discoveries Inc Tratamientos contra el cáncer usando combinaciones de inhibidores de la ruta de PI3K/Akt y ERK
WO2015095835A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods of modulating radioiodine uptake for the treatment of radioiodine-refractory cancers
EP3082779B1 (en) * 2013-12-20 2023-06-07 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of type 2 mek and erk inhibitors
WO2015095831A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of mtor and erk inhibitors
JP7180977B2 (ja) * 2015-01-30 2022-11-30 バイオメッド バレー ディスカバリーズ，インコーポレイティド 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩
NZ772411A (en) 2015-01-30 2022-05-27 Vertex Pharma Crystalline forms of c21h22ci2n4o2
WO2016187028A1 (en) * 2015-05-15 2016-11-24 Celgene Avilomics Research, Inc. Heteroaryl compounds, synthesis thereof, and intermediates thereto
CN107849046B (zh) * 2015-06-03 2020-06-12 常州捷凯医药科技有限公司 作为erk抑制剂的杂环化合物
CA2987963C (en) 2015-06-03 2023-01-24 Js Innopharm (Shanghai) Ltd. Heterocyclic compounds for treating psoriasis
MA47013A (fr) 2015-10-21 2018-08-29 Otsuka Pharma Co Ltd Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase
EP3170822A1 (en) 2015-11-18 2017-05-24 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
MX2019003938A (es) 2016-10-05 2019-06-10 Zeno Royalties & Milestones Llc Compuestos espirociclicos.
GB201706327D0 (en) 2017-04-20 2017-06-07 Otsuka Pharma Co Ltd A pharmaceutical compound
US11406627B2 (en) * 2017-10-12 2022-08-09 Novartis Ag Combinations of MDM2 inhibitors with inhibitors of ERK for treating cancers
WO2019180141A1 (en) 2018-03-23 2019-09-26 Bayer Aktiengesellschaft Combinations of rogaratinib
WO2021020841A1 (en) * 2019-07-29 2021-02-04 Standigm Inc. Composition for preventing or treating metabolic liver disease
EP4212531A1 (en) 2022-01-14 2023-07-19 AGV Discovery Azaindole derivatives and their use as erk kinase inhibitors
WO2023169480A1 (zh) * 2022-03-08 2023-09-14 甘李药业股份有限公司 氘代化合物，及其制备方法和应用
TW202400572A (zh) * 2022-03-24 2024-01-01 美商生物醫學谷探索公司 Erk的吡咯抑制劑之氘化類似物、其合成及其中間物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5565413A (en) * 1994-12-06 1996-10-15 Zeneca Limited Substituted pyridyl phenyl ketone herbicides
US5472966A (en) * 1995-03-29 1995-12-05 Bristol-Myers Squibb Company Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
AU5566300A (en) * 1999-06-22 2001-01-09 Takeda Chemical Industries Ltd. Acylhydrazine derivatives, process for preparing the same and use thereof
MY130778A (en) * 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
EP1506189A1 (en) * 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
CA2491895C (en) * 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
ES2392426T3 (es) * 2002-07-18 2012-12-10 Janssen Pharmaceutica Nv Inhibidores de quinasas con triazina sustituida
GB0217780D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
EP1546117A2 (en) * 2002-08-14 2005-06-29 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
JP4808154B2 (ja) * 2003-03-13 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用な組成物
WO2005113541A1 (en) * 2004-05-14 2005-12-01 Vertex Pharmaceuticals, Incorporated Pyrrole compounds as inhibitors of erk protein kinase, synthesis thereof and intermediates thereto

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10634677B2 (en) 2013-10-14 2020-04-28 Indiana University Research And Technology Corporation Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD
US11733243B2 (en) 2013-10-14 2023-08-22 Indiana University Research And Technology Corporation Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD

Also Published As

Publication number Publication date
PT3305776T (pt) 2019-12-17
BRPI0511111A (pt) 2007-11-27
CN1976919A (zh) 2007-06-06
RU2006144445A (ru) 2008-06-20
AR106755A2 (es) 2018-02-14
AR051735A1 (es) 2007-02-07
EP2799434B1 (en) 2017-08-02
HK1203505A1 (en) 2015-10-30
EP1753738A1 (en) 2007-02-21
JP5132305B2 (ja) 2013-01-30
JP2007537295A (ja) 2007-12-20
EP3608315A1 (en) 2020-02-12
MXPA06013209A (es) 2007-01-16
RU2376299C2 (ru) 2009-12-20
USRE47318E1 (en) 2019-03-26
EP1753738B1 (en) 2014-07-09
NZ551582A (en) 2011-01-28
ES2651439T3 (es) 2018-01-26
DK3305776T3 (da) 2019-12-09
CA2566461A1 (en) 2005-12-01
NO20065727L (no) 2006-12-12
ES2513965T3 (es) 2014-10-27
IL179207A0 (en) 2007-03-08
AU2005245885B2 (en) 2011-01-20
CY1122336T1 (el) 2021-01-27
ES2751761T3 (es) 2020-04-01
USRE48266E1 (en) 2020-10-20
EP3305776A1 (en) 2018-04-11
TW200607803A (en) 2006-03-01
US20060106069A1 (en) 2006-05-18
US7354939B2 (en) 2008-04-08
SI3305776T1 (sl) 2020-01-31
US20230183276A1 (en) 2023-06-15
WO2005113541A1 (en) 2005-12-01
PL3305776T3 (pl) 2020-03-31
CA2566461C (en) 2012-07-10
ZA200609975B (en) 2008-02-27
EP3943489A1 (en) 2022-01-26
HK1247910A1 (zh) 2018-10-05
USRE46097E1 (en) 2016-08-09
EP3305776B1 (en) 2019-09-25
AU2005245885A1 (en) 2005-12-01
ES2897422T3 (es) 2022-03-01
LT3305776T (lt) 2020-01-10
USRE49500E1 (en) 2023-04-25
EP3608315B1 (en) 2021-08-11
HUE047130T2 (hu) 2020-04-28
EP2799434A1 (en) 2014-11-05

Similar Documents

Publication Publication Date Title
UA84930C2 (ru) Пиррольные соединения как ингибиторы протеинкиназ erk, их синтез и соответствующие промежуточные соединения
HK1116349A1 (en) Pyrrolopyrimidines useful as inhibitors of protein kinase
SG166827A1 (en) Aminopyrimidines useful as kinase inhibitors
HK1113569A1 (en) Pyrazolo
TW200633980A (en) Pyridones useful as inhibitors of kinases
TW200604168A (en) Azaindoles useful as inhibitors of rock and other protein kinases
SG151327A1 (en) Deazapurines useful as inhibitors of janus kinases
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
WO2005105780A3 (en) Compositions useful as inhibitors of rock and other protein kinases
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
ATE466580T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
ATE450530T1 (de) Zusammensetzungen zur verwendung als protein- kinase-inhibitoren
ATE542814T1 (de) Pyrazinkinaseinhibitoren
UA84929C2 (en) Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors
MX2009004771A (es) Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa.
MX2009010127A (es) Compuestos utiles como inhibidores de janus cinasas.
TW200745088A (en) Benzimidazoles useful as inhibitors of protein kinases
MX2009005231A (es) Composiciones utiles como inhibidores de proteina cinasa.